DRUG vs. IMNM, EOLS, AUTL, ERAS, ORIC, VECT, KURA, TECX, CRGX, and HUMA
Should you be buying Bright Minds Biosciences stock or one of its competitors? The main competitors of Bright Minds Biosciences include Immunome (IMNM), Evolus (EOLS), Autolus Therapeutics (AUTL), Erasca (ERAS), ORIC Pharmaceuticals (ORIC), VectivBio (VECT), Kura Oncology (KURA), Tectonic Therapeutic (TECX), CARGO Therapeutics (CRGX), and Humacyte (HUMA). These companies are all part of the "pharmaceutical products" industry.
Bright Minds Biosciences vs.
Bright Minds Biosciences (NASDAQ:DRUG) and Immunome (NASDAQ:IMNM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, community ranking, dividends, profitability and media sentiment.
Bright Minds Biosciences has a beta of -6.52, indicating that its share price is 752% less volatile than the S&P 500. Comparatively, Immunome has a beta of 1.9, indicating that its share price is 90% more volatile than the S&P 500.
Immunome received 28 more outperform votes than Bright Minds Biosciences when rated by MarketBeat users. However, 100.00% of users gave Bright Minds Biosciences an outperform vote while only 74.42% of users gave Immunome an outperform vote.
Bright Minds Biosciences presently has a consensus target price of $80.00, suggesting a potential upside of 117.51%. Immunome has a consensus target price of $28.83, suggesting a potential upside of 188.62%. Given Immunome's higher probable upside, analysts clearly believe Immunome is more favorable than Bright Minds Biosciences.
Bright Minds Biosciences has higher earnings, but lower revenue than Immunome. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.
Bright Minds Biosciences has a net margin of 0.00% compared to Immunome's net margin of -3,014.59%. Bright Minds Biosciences' return on equity of -48.03% beat Immunome's return on equity.
40.5% of Bright Minds Biosciences shares are held by institutional investors. Comparatively, 44.6% of Immunome shares are held by institutional investors. 42.7% of Bright Minds Biosciences shares are held by insiders. Comparatively, 8.6% of Immunome shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, Immunome had 9 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 12 mentions for Immunome and 3 mentions for Bright Minds Biosciences. Immunome's average media sentiment score of 0.63 beat Bright Minds Biosciences' score of 0.59 indicating that Immunome is being referred to more favorably in the news media.
Summary
Immunome beats Bright Minds Biosciences on 10 of the 18 factors compared between the two stocks.
Get Bright Minds Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for DRUG and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bright Minds Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:DRUG) was last updated on 1/18/2025 by MarketBeat.com Staff
Free DRUG Stock Alerts